Nucana reports second quarter 2024 financial results and provides business update

Key data readouts on track for all programs in 2024 anticipated cash runway into q1 2025 edinburgh, united kingdom, aug. 15, 2024 (globe newswire) -- nucana plc (nasdaq: ncna) announced financial results for the second quarter ended june 30, 2024 and provided an update on its broad clinical development program with its transformative protide therapeutics. as of june 30, 2024, nucana had cash and cash equivalents of £11.6 million compared to £12.9 million as of march 31, 2024 and £17.2 million at december 31, 2023.
NCNA Ratings Summary
NCNA Quant Ranking